Cell and Gene therapy - it's role in fighting disease

Cell and gene therapies promise life-changing treatments for severe diseases such as cancer. But the pandemic has hit the sector hard. Supply chain disruptions and including the timely delivery of therapies to clinical sites and patients have been daunting. Research and development programs have been pushed back by around 6-8 months and now a lot of CGT companies are revaluating their business models for the future as they surface out of the challenges. Funding has dried out and government stimulus seems like a far cry.

Spotlight Question

How can the CGT companies adapt and become resilient? What are the longer-term challenges facing the sector and what can governments do to ensure they remain operable and viable?